Steven T. Harris, MD, FACP, is Clinical Professor of Medicine at the University of California, San Francisco.

Dr Harris received his medical degree from the University of California, San Francisco, where he completed an internship and residency/chief residency in Internal Medicine. Subsequent postdoctoral training included a fellowship in endocrinology and metabolism at Massachusetts General Hospital in Boston.

Dr Harris has directed his research efforts toward the prevention and treatment of osteoporosis, focusing on the effects of nutrition, calcium supplementation, vitamin D, hormone therapy, bisphosphonates, calcitonin, parathyroid hormone, and selective estrogen receptor modulators. A frequent contributor to the medical literature, Dr Harris has published in such prominent journals as the Journal of Clinical Endocrinology and Metabolism, Osteoporosis International, Journal of Bone and Mineral Research, and the Journal of the American Medical Association. In addition, Dr Harris has been invited to speak at annual meetings of the Endocrine Society and the American Association of Clinical Endocrinologists.

A Fellow of the American College of Physicians, Dr Harris is also a member of the National Osteoporosis Foundation, the American Society for Bone and Mineral Research, the American Association of Clinical Endocrinologists, the Endocrine Society, the International Bone and Mineral Society, and the International Society for Clinical Densitometry.

Frederick R. Singer, MD, is Clinical Professor of Medicine at the David Geffen School of Medicine at the University of California, Los Angeles. He is also Director of the Endocrine/Bone Disease Program and Director of the Skeletal Biology Laboratory at the John Wayne Cancer Institute at Saint John’s Hospital and Health Center in Santa Monica.

Dr Singer received his medical degree from the University of California School of Medicine, San Francisco. He completed an internship at the University of California Affiliated Hospitals in Los Angeles and a residency in Internal Medicine at Wadsworth Veterans Administration Hospital, also in Los Angeles. Postdoctoral training includes a research fellowship at the Royal Postgraduate Medical School of London, in England, and a clinical and research fellowship in the Endocrine Unit of Massachusetts General Hospital in Boston.

Dr Singer’s research has focused on the etiology and treatment of Paget’s disease of bone, hyperparathyroidism, and abnormal bone metabolism in cancer patients. A significant contributor to the medical literature in endocrinology, Dr Singer has contributed well over 200 publications, including chapters, books, and invited articles for such prominent journals as Proceedings of the National Academy of Science, The New England Journal of Medicine, Cancer Research, Journal of Clinical Investigation, and the Journal of Bone and Mineral Research.

Since 1989, Dr Singer has served as Chairman of the Board of Directors of the Paget Foundation. He is past president of the American Society for Bone and Mineral Research and served as Cochairman of the Second North American Symposium on Skeletal Complications of Malignancy at the National Institutes of Health, and as Chairman of the National Cancer Institute Special Study Section on Molecular Interactions Between Tumor Cells and Bone.

Graham Russell, MD, PhD, is the Norman Collisson Professor of Musculoskeletal Sciences; Director, Oxford University Institute of Musculoskeletal Sciences (Botnar Research Centre); Professor and Head of the Nuffield Department of Orthopaedic Surgery; and Professorial Fellow, St. Peter’s College at the University of Oxford in Oxford, England.

Dr Russell received his doctoral degree from the Medical Research Council Mineral Metabolism Unit and Department of Chemical Pathology at the University of Leeds Medical School, Leeds, England, and his doctor of medicine degree from Oxford University Medical School, Oxford.

Dr Russell has worked in the field of calcium metabolism and bone diseases throughout his career and has played a key role in identifying the biological and clinical effects of bisphosphonates, including successful applications of this class of drugs in Paget’s disease of bone. He is involved in ongoing studies to assess the molecular mechanisms of action of bisphosphonates and in the development of novel therapies. A prolific writer, Dr Russell has published numerous articles on the pharmacokinetics and mechanisms of action of bisphosphonates, clinical disorders of bone resorption, and calcium metabolism in such journals as Lancet, British Medical Journal, The New England Journal of Medicine, and the Journal of Bone and Mineral Research.

Dr Russell is past president of the International Bone and Mineral Society, a founding member of the National Osteoporosis Society (UK), and past chairman of its Council of Management. Among awards he has received for his contributions are the John B. Johnson award of The Paget Foundation for Paget’s Disease of Bone and Related Disorders, and the W.F. Neuman award of the American Society for Bone and Mineral Research.

Faculty Disclosure Declarations
Medical Education Resource’s policy is to insure balance, independence, objectivity, and scientific rigor in all sponsored or jointly sponsored educational programs. We must disclose to the program audience any real or apparent conflict(s) of interest with companies whose products or services may be mentioned in the faculty’s presentations. The faculty reported the following:

Steven T. Harris, MD, FACP
Steven T. Harris, MD, FACP, is a consultant for the following: Amgen, Eli Lilly and Company, GlaxoSmithKline, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Procter & Gamble Pharmaceuticals, Roche, Sanofi Pasteur Inc., and Wyeth. He has made presentations for the following: Eli Lilly and Company, GlaxoSmithKline, Merck & Co., Inc., Procter & Gamble Pharmaceuticals, Roche, Sanofi Pasteur Inc., and Wyeth. He does plan an off-label discussion on: annual intravenous infusion of zoledronic acid, quarterly intravenous injection of ibandronate, possible monthly oral administration of alendronate or risedronate, subcutaneous injection of AMG 162, cyclical administration of teriparatide, combination therapy with teriparatide and an antiresorptive agent, daily injection of PTH (1-84), oral administration of calcilytic compounds, and oral administration of cathepsin K inhibitor.

Frederick R. Singer, MD
Frederick R. Singer, MD, is a consultant for the following: Merck & Co., Inc., Novartis Pharmaceuticals Corporation, and Procter & Gamble Pharmaceuticals. He is a speakers bureau member for Merck & Co., Inc. and Novartis Pharmaceuticals Corporation. He does plan to discuss off-label use of products.

Graham Russell, MD, PhD
Graham Russell, MD, PhD, is a consultant for the following: Alliance for Better Bone Health (Procter & Gamble Pharmaceuticals and Sanofi Pasteur Inc.), Novartis Pharmaceuticals Corporation, and GlaxoSmithKline/Roche. He has received grants and research support from Alliance for Better Bone Health (Procter & Gamble Pharmaceuticals and Sanofi Pasteur Inc.). He does plan to discuss off-label use of products.

Paul D. Miller, MD
Paul D. Miller, MD, is a consultant for the following: Amgen, Eli Lilly and Company, GlaxoSmithKline, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, NPS, Procter & Gamble Pharmaceuticals, Roche, and Sanofi Pasteur Inc. He has received scientific grants from the following: Amgen, Eli Lilly and Company, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Pharmacia, Procter & Gamble Pharmaceuticals, Roche, and Sanofi Pasteur Inc. Although not present at this evening’s program, Dr Miller assisted in the development of this symposium.